Komori
Occurring Fact4883Modalis Therapeutics CorporationPharmaceuticals

Notice Regarding the Recording of Non-Operating Income (Foreign Exchange Gains)

In the first quarter of the fiscal year ending December 2026, we recognized a foreign exchange gain of ¥14 million arising from fluctuations in foreign exchange rates as non-operating income. This impact is reflected in the Summary of First-Quarter Financial Results released on the same day.

Worth reading
36Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
14
¥ million
Wording
Conditional
How definitive the wording is.

Recognition of Non-Operating Income (Foreign Exchange Gain)

Subject Entity

Our group (reporting company: Modalis Therapeutics Corporation)

Occurrence1 January 2026 to 31 March 2026 (the first quarter of the fiscal year ending December 2026, consolidated accounting period)
This disclosure05/13/2026
Cause

This arose mainly on foreign-currency-denominated assets and liabilities held by our group as a result of fluctuations in foreign exchange rates.

Amount of Impact on Business Performance

Foreign exchange gain of ¥14 million (non-operating income)

Accounting period in which recognized

The first quarter of the fiscal year ending December 2026, consolidated accounting period (1 January 2026 to 31 March 2026)

Impact on Earnings Forecast

No information is provided regarding the impact on the earnings forecast. Reflected in the Summary of First-Quarter Financial Results for the fiscal year ending December 2026.

Outlook

This amount may fluctuate depending on future foreign exchange market conditions.

Event that occurred
ItemDetails
Event nameRecognition of Non-Operating Income (Foreign Exchange Gain)
Date of occurrence1 January 2026 to 31 March 2026 (the first quarter of the fiscal year ending December 2026, consolidated accounting period)
Subject EntityOur group (reporting company: Modalis Therapeutics Corporation)
CauseThis arose mainly on foreign-currency-denominated assets and liabilities held by our group as a result of fluctuations in foreign exchange rates.
Amount of Impact on Business PerformanceForeign exchange gain of ¥14 million (non-operating income)
Accounting period in which recognizedThe first quarter of the fiscal year ending December 2026, consolidated accounting period (1 January 2026 to 31 March 2026)
Impact on Earnings ForecastNo information is provided regarding the impact on the earnings forecast. Reflected in the Summary of First-Quarter Financial Results for the fiscal year ending December 2026.
OutlookThis amount may fluctuate depending on future foreign exchange market conditions.
Items this document does not state (17)
Date recognized / date notice receivedTarget Locations / ProductsType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the changePlanned follow-up disclosure

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Foreign exchange gains arose mainly on foreign-currency-denominated assets and liabilities held by our group as a result of fluctuations in foreign exchange rates.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Recording of Non-Operating Income (Foreign Exchange Gains) | Modalis Therapeutics Corporation (4883) timely disclosure | Komori